Zhongguo linchuang yanjiu (Dec 2023)
Effects of liraglutide on neurological function and levels of serum VEGF and bFGF in type 2 diabetes patients with acute cerebral infarction
Abstract
Objective To investigate the therapeutic effect of liraglutide on acute cerebral infarction (ACI) in patients with type 2 diabetes mellitus (T2DM), and its effect on neurological function and serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). Methods A total of 160 patients with ACI accompanied by T2DM admitted to Haikou People's Hospital from March 2020 to March 2022 were randomly divided into observation group and control group (n=80, each). Both groups of patients were given routine treatment for ACI. On this basis, the control group was treated with insulin aspart and insulin glargine, while the observation group was treated with liraglutide and insulin glargine. Both groups received continuous treatment for 3 months. In addition to clinical efficacy, fasting blood glucose (FBG) before and after treatment, 2-hour postprandial blood glucose (2hPG), hemoglobin A1c (HbA1c), insulin resistance index (HOMA-IR), National Institutes of Health Stroke Scale (NIHSS), and modified Rankin Scale (mRS) scores of two groups of patients was compared. Enzyme linked immunosorbent assay was used to detect the levels of serum VEGF and bFGF before treatment and after 1 and 3 months of treatment in both groups. Results After treatment, the levels of FBG, bFGF, HbA1c, HOMA-IR, and the scores of NIHSS and mRS in the observation group decreased compared to those before treatment, and the above indicators levels in the observation group were significantly lower than those in the control group (P＜0.05). The total clinical effective rate of the observation group was significantly higher than that of the control group ［95.00%(76/80) vs 83.75%(67/80), χ2=5.331, P=0.021］. After treatment, the levels of serum VEGF and bFGF showed a gradual downward trend in both groups (P＜0.05). After 1 month and 3 months of treatment, the serum VEGF and bFGF levels in the observation group were significantly higher than those in the control group (P＜0.05). Conclusion Liraglutide combined with insulin glargine can effectively control blood sugar, reduce insulin resistance, alleviate neurological damage, upregulate serum VEGF and bFGF levels, and improve clinical efficacy in T2DM patients with ACI.
Keywords
